Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue

Biotechnology Journal

Volumn 9, Issue 4, 2014, Pages 501-510

  Schneider, Jeannine D ^a   Castilho, Alexandra ^a   Neumann, Laura ^a   Altmann, Friedrich ^a   Loos, Andreas ^a   Kannan, Latha ^b   Mor, Tsafrir S ^b   Steinkellner, Herta ^a  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Butyrylcholinesterase; Glycoengineering; Plants; Recombinant biopharmaceuticals; Sialic acid

Indexed keywords

ESTERIFICATION; POLYSACCHARIDES; PROTEINS;

BIOPHARMACEUTICALS; BUTYRYLCHOLINESTERASE; GLYCOENGINEERING; PLANTS; SIALIC ACIDS;

GLYCOSYLATION;

ALPHA 1,3 FUCOSYLTRANSFERASE; CHOLINESTERASE; FUCOSE; GLYCAN DERIVATIVE; PLASMA DERIVED PROTEIN; PROTEIN; SIALIC ACID; UNCLASSIFIED DRUG; XYLOSE; BUTYRYLTHIOCHOLINE; N ACETYLNEURAMINIC ACID; RECOMBINANT PROTEIN;

APOPLAST; ARABIDOPSIS THALIANA; ARTICLE; CARBOHYDRATE SYNTHESIS; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME GLYCOSYLATION; ENZYME STABILITY; GENE OVEREXPRESSION; GLYCOSYLATION; HUMAN; LIQUID CHROMATOGRAPHY; NICOTIANA BENTHAMIANA; NONHUMAN; PRIORITY JOURNAL; SIALYLATION; TOBACCO MOSAIC VIRUS; WESTERN BLOTTING; CHEMISTRY; GENETICS; METABOLISM; PROTEIN ENGINEERING; TOBACCO; TRANSGENIC PLANT;

EQUIDAE; NICOTIANA BENTHAMIANA;

BUTYRYLCHOLINESTERASE; BUTYRYLTHIOCHOLINE; GLYCOSYLATION; HUMANS; N-ACETYLNEURAMINIC ACID; PLANTS, GENETICALLY MODIFIED; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; TOBACCO;

EID: 84897094860     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201300229     Document Type: Article

References (32)

1. Doctor, B. P., Saxena, A., Bioscavengers for the protection of humans against organophosphate toxicity. Chem.-Biol. Interact. 2005, XX, 167-171.
2. Mumford, H., Docx, C. J., Price, M. E., Green, A. C. et al., Human plasma-derived BuChE as a stoichiometric bioscavenger for treatment of nerve agent poisoning. Chem.-Biol. Interact. 2013, 203, 160-166.
3. Mumford, H., Troyer, J. K., Post-exposure therapy with recombinant human BuChE following percutaneous VX challenge in guinea-pigs. Toxicol. Lett. 2011, 206, 29-34.
4. Geyer, B. C., Kannan, L., Garnaud, P. E., Broomfield, C. A. et al., Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agents. Proc. Natl. Acad. Sci. USA 2010, 107, 20251-20256.
5. Geyer, B. C., Kannan, L., Cherni, I., Woods, R. R. et al., Transgenic plants as a source for the bioscavenging enzyme, human butyrylcholinesterase. Plant Biotechnol. J. 2010, 8, 873-886.
6. Ilyushin, D. G., Smirnov, I. V., Belogurov, A. A. Jr., Dyachenko, I. A. et al., Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo. Proc. Natl. Acad. Sci. USA 2013, 110, 1243-1248.
7. Li, H., Schopfer, L. M., Masson, P., Lockridge, O., Lamellipodin proline rich peptides associated with native plasma butyrylcholinesterase tetramers. Biochem. J. 2008, 411, 425-432.
8. Kolarich, D., Weber, A., Pabst, M., Stadlmann, J. et al., Glycoproteomic characterization of butyrylcholinesterase from human plasma. Proteomics 2008, 8, 254-263.
9. Saxena, A., Ashani, Y., Raveh, L., Stevenson, D. et al., Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases. Mol. Pharmacol. 1998, 53, 112-122.
10. Kronman, C., Chitlaru, T., Elhanany, E., Velan, B., Shafferman, A., Hierarchy of post-translational modifications involved in the circulatory longevity of glycoproteins. Demonstration of concerted contributions of glycan sialylation and subunit assembly to the pharmacokinetic behavior of bovine acetylcholinesterase. J. Biol. Chem. 2000, 275, 29488-29502.
11. Huang, Y. J., Huang, Y., Baldassarre, H., Wang, B. et al., Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc. Natl. Acad. Sci. USA 2007, 104, 13603-13608.
12. Li, S., Ip, D. T., Lin, H. Q., Liu, J. M. et al., High-level expression of functional recombinant human butyrylcholinesterase in silkworm larvae by Bac-to-Bac system. Chem.-Biol. Interact. 2010, 187, 101-105.
13. Lenz, D. E., Maxwell, D. M., Koplovitz, I., Clark, C. R., et al., Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem.-Biol. Interact. 2005, 205-210.
14. Duysen, E. G., Bartels, C. F., Lockridge, O., Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity. J. Pharmacol. Exp. Ther. 2002, 302, 751-758.
15. Castilho, A., Steinkellner, H., Glyco-engineering in plants to produce human-like N-glycan structures. Biotechnol. J. 2012, 7, 1088-1098.
16. Bosch, D., Castilho, A., Loos, A., Schots, A., Steinkellner, H., N-Glycosylation of plant-produced recombinant proteins. Curr. Pharm. Des. 2013, 19, 5503-5512.
17. Castilho, A., Strasser, R., Stadlmann, J., Grass, J. et al., In planta protein sialylation through overexpression of the respective mammalian pathway. J. Biol. Chem. 2010, 285, 15923-15930.
18. Castilho, A., Gattinger, P., Grass, J., Jez, J. et al., N-glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans. Glycobiology 2011, 21, 813-823.
19. Castilho, A., Neumann, L., Gattinger, P., Strasser, R. et al., Generation of biologically active multi-sialylated recombinant human EPOFc in plants. PloS One 2013, 8, e54836.
20. Strasser, R., Steinkellner, H., Boren, M., Altmann, F. et al., Molecular cloning of cDNA encoding N-acetylglucosaminyltransferase II from Arabidopsis thaliana. Glycoconj. J. 1999, 16, 787-791.
21. Strasser, R., Stadlmann, J., Svoboda, B., Altmann, F. et al., Molecular basis of N-acetylglucosaminyltransferase I deficiency in Arabidopsis thaliana plants lacking complex N-glycans. Biochem. J. 2005, 387, 385-391.
22. Strasser, R., Stadlmann, J., Schahs, M., Stiegler, G. et al., Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 2008, 6, 392-402.
23. Stadlmann, J., Pabst, M., Kolarich, D., Kunert, R., Altmann, F., Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 2008, 8, 2858-2871.
24. Pabst, M., Chang, M., Stadlmann, J., Altmann, F., Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140. Biol. Chem. 2012, 393, 719-730.
25. Ellman, G. L., Courtney, K. D., Andres, V. Jr., Feather-Stone, R. M., A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95.
26. Nagels, B., Van Damme, E. J., Pabst, M., Callewaert, N., Weterings, K., Production of complex multiantennary N-glycans in Nicotiana benthamiana plants. Plant Physiol. 2011, 155, 1103-1112.
27. Egrie, J. C., Browne, J. K., Development and characterization of novel erythropoiesis stimulating protein (NESP). Br. J. Cancer 2001, 84Suppl1, 3-10.
28. Castilho, A., Bohorova, N., Grass, J., Bohorov, O. et al., Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody. PloS One 2011, 6, e26040.
29. Lombardi, R., Donini, M., Villani, M. E., Brunetti, P. et al., Production of different glycosylation variants of the tumour-targeting mAb H10 in Nicotiana benthamiana: influence on expression yield and antibody degradation. Transgenic Res. 2012, 21, 1005-1021.
30. Hehle, V. K., Paul, M. J., Drake, P. M., Ma, J. K., van Dolleweerd, C. J., Antibody degradation in tobacco plants: a predominantly apoplastic process. BMC Biotechnol. 2011, 11, 128.
31. van der Hoorn, R. A., Plant proteases: From phenotypes to molecular mechanisms. Annu. Rev. Plant Biol. 2008, 59, 191-223.
32. Schillberg, S., Raven, N., Fischer, R., Twyman, R. M., Schiermeyer, A., Molecular farming of pharmaceutical proteins using plant suspension cell and tissue cultures. Curr. Pharm. Des. 2013, 19, 5531-5542.